CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $3.7B, above the global median of $1.18B
- FinancialsAltman Z-Score 7.19: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
355.47BINR3.70B · vs all stocks (USD)
Trailing P/E
86.98xRevenue (TTM)
36.53BINR380.68M · vs all stocks (USD)
Profit Margin
11.20%Beta
0.9740xvs all stocks
52-Week Change
44.30%vs all stocks
Market Capitalization
355.47BINR3.70B · vs all stocks (USD)
Enterprise Value
375.07BINR3.91B · vs all stocks (USD)
Trailing P/E
86.98xPEG Ratio
-0.1682xPrice to Sales (TTM)
9.73xPrice to Book (MRQ)
7.29xEnterprise to Revenue
10.27xEnterprise to EBITDA
50.13xGross Margin
65.55%Profit Margin
11.20%Operating Margin
14.32%Return on Assets (TTM)
2.47%Return on Equity (TTM)
4.03%Revenue (TTM)
36.53BINR380.68M · vs all stocks (USD)
Revenue per Share (TTM)
225.13INRUpdated Sep 29, 2026Quarterly Revenue Growth
25.90%Gross Profit (TTM)
23.80BINR248.02M · vs all stocks (USD)
EBITDA (TTM)
7.87BINR82.01M · vs all stocks (USD)
Net Income (TTM)
4.09BINR42.62M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
25.03%Operating Cash Flow (TTM)
3.90BINR40.64M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
2.13BINR22.20M · vs all stocks (USD)
Payout Ratio
0.00%Minority Interest (Equity)
3.41BINRFY2026 · Mar 31, 2026Revenue
33.73BINRFY2026 · Mar 31, 2026Cost of Goods Sold
11.32BINRFY2026 · Mar 31, 2026Gross Profit
22.41BINRFY2026 · Mar 31, 2026Operating Income
4.03BINR42.00M · vs all stocks (USD)
Pre-tax Income
2.38BINRFY2026 · Mar 31, 2026Income Tax Expense
390.00MINRFY2026 · Mar 31, 2026Net Income
1.99BINRFY2026 · Mar 31, 2026EBIT
4.51BINRFY2026 · Mar 31, 2026EBITDA (Income Statement)
7.63BINRFY2026 · Mar 31, 2026Other Operating Expenses
8.86BINRFY2026 · Mar 31, 2026Non-operating Interest Expense
2.13BINRFY2026 · Mar 31, 2026Minority Interests (P&L)
140.00MINRFY2026 · Mar 31, 2026Preferred Stock Dividends
0.00INRFY2026 · Mar 31, 2026Operating Cash Flow
2.71BINRFY2026 · Mar 31, 2026Free Cash Flow
1.85BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents (End of Period)
2.17BINRFY2026 · Mar 31, 2026Starting Profit (CF Statement)
2.38BINRFY2026 · Mar 31, 2026Stock-based Compensation
40.00MINRFY2026 · Mar 31, 2026Other Non-cash Items
3.11BINRFY2026 · Mar 31, 2026Change in Accounts Receivable (CF)
500.00MINRFY2026 · Mar 31, 2026Change in Other Assets/Liabilities
-3.32BINRFY2026 · Mar 31, 2026Capital Expenditures
-860.00MINRFY2026 · Mar 31, 2026Net Intangibles (CF)
-2.28BINRFY2026 · Mar 31, 2026Sale of Investments
390.00MINRFY2026 · Mar 31, 2026Other Investing Activity
290.00MINRFY2026 · Mar 31, 2026Net Investing Cash Flow
-180.00MINRFY2026 · Mar 31, 2026Long-term Debt Issuance
7.37BINRFY2026 · Mar 31, 2026Long-term Debt Payments
-5.25BINRFY2026 · Mar 31, 2026Net Short-term Debt Issuance
-700.00MINRFY2026 · Mar 31, 2026Net Financing Cash Flow
1.42BINRFY2026 · Mar 31, 2026Shares Outstanding
162.49MSharesUpdated Sep 29, 2026Float Shares
76.59MSharesUpdated Sep 29, 2026% Held by Insiders
51.02%vs all stocks
% Held by Institutions
13.41%vs all stocks
Total Cash (MRQ)
6.80BINR70.86M · vs all stocks (USD)
Total Cash per Share (MRQ)
41.85INRUpdated Sep 29, 2026Total Debt (MRQ)
22.33BINR232.70M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.4228xCurrent Ratio (MRQ)
1.66xBook Value per Share (MRQ)
299.95INRUpdated Sep 29, 2026Total Assets
86.15BINR897.77M · vs all stocks (USD)
Total Current Assets
26.97BINRFY2026 · Mar 31, 2026Total Liabilities
33.34BINRFY2026 · Mar 31, 2026Total Non-current Assets
59.18BINRFY2026 · Mar 31, 2026Total Non-current Liabilities
17.12BINRFY2026 · Mar 31, 2026Total Current Liabilities
16.22BINRFY2026 · Mar 31, 2026Cash
2.17BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents
2.17BINRFY2026 · Mar 31, 2026Other Short-term Investments
4.12BINRFY2026 · Mar 31, 2026Accounts Receivable
5.88BINRFY2026 · Mar 31, 2026Inventory
8.87BINRFY2026 · Mar 31, 2026Accounts Payable
5.63BINRFY2026 · Mar 31, 2026Short-term Debt
6.77BINRFY2026 · Mar 31, 2026Other Current Liabilities
130.00MINRFY2026 · Mar 31, 2026Long-term Debt
15.56BINRFY2026 · Mar 31, 2026Other Non-current Liabilities
640.00MINRFY2026 · Mar 31, 2026Common Stock (Book)
810.00MINRFY2026 · Mar 31, 2026Retained Earnings
4.63BINRFY2026 · Mar 31, 2026Total Shareholders' Equity
52.81BINR550.33M · vs all stocks (USD)
52-Week Low
1.09KINRUpdated Sep 29, 202652-Week High
2.42KINRUpdated Sep 29, 202652-Week Change
44.30%vs all stocks
Beta
0.9740xvs all stocks
50-Day MA
2.00KINRUpdated Sep 29, 2026200-Day MA
1.64KINRUpdated Sep 29, 2026Avg 10-Day Volume
1.21MSharesUpdated Sep 29, 2026Avg 30-Day Volume
1.10MSharesUpdated Sep 29, 2026Diluted EPS (TTM)
25.15INRUpdated Sep 29, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 7.19: safe zoneNotable
Altman Z-Score: 7.19
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $3.7B, above the global median of $1.18BNotable
Market cap (USD): 3,704,330,831.179Global Median: 1,180,223,658.953
Levered free cash flow is $22.2M, above the global median of $18.73MNotable
Levered free cash flow (USD): 22,196,730Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Beijing Tiantan Biological Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Huahai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
China Grand Pharmaceutical and Healthcare Holdings Limited
Tier 1ProductionApproval-Gated PipelineRule
Amylyx Pharmaceuticals, Inc. Common Stock
Tier 1ProductionApproval-Gated PipelineRule
Irhythm Technologies Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Shijiazhuang Yiling Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ambu A/S
Tier 1ProductionApproval-Gated PipelineRuleFlow
Organon & Co.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Relay Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Acadia Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk